1793052-96-6

1793052-96-6 structure

Name: SRS16-86
Chemical Name: SRS16-86
CAS Number: 1793052-96-6
Molecular Formula: C₂₆H₃₂N₄O₂
Molecular Weight: 432.558
Catalog: Signaling Pathways Apoptosis Ferroptosis
Create Date: 2021-01-08 17:39:23
Modify Date: 2024-01-12 10:47:31
SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].

Name	SRS16-86
Synonyms	Benzoic acid, 3-[[(1Z)-5-pyrimidinylmethylene]amino]-4-(tricyclo[3.3.1.13,7]dec-1-ylamino)-, 1,1-dimethylethyl ester 2-Methyl-2-propanyl 4-[(3s,5s,7s)-adamantan-1-ylamino]-3-[(Z)-(5-pyrimidinylmethylene)amino]benzoate SRS16-86

Description	SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].
Related Catalog	Signaling Pathways >> Apoptosis >> Ferroptosis Research Areas >> Inflammation/Immunology
In Vitro	SRS16-86 (1 µM; 24 hours; in the presence or absence of erastin) inhibits ferroptosis in HT-1080 cells and NIH 3T3 cells[2].
In Vivo	SRS16-86 (intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery) protects mice from functional acute renal failure and structural organ damage after ischemia–reperfusion injury (IRI)[2]. SRS16-86 (intraperitoneal injection; 2 mg/kg; 4 weeks) combination therapy with [Nec-1+SfA] is superior in the prevention of renal IRI compared with the double-combination therapy with [Nec-1+SfA]. Addition of 16-86 reduces plasma levels of serum urea and serum creatinine in IRI mice model[2]. SRS16-86 (intraperitoneal injection; 15 mg/kg; once a day; 7 days) enhances functional recovery after SCI, it decreases the levels of proinflammatory cytokines and the inflammatory adhesion factor in injured spinal cord in rats[3]. Animal Model: Renal IRI model Dosage: 2 mg/kg; 15 min before the onset of surgery Administration: Intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery Result: Was protective from renal IRI. Animal Model: Renal IRI model Dosage: 2 mg/kg Administration: Combination with Necrostatin-1/Sanglifehrin A; 2 mg/kg; 4 weeks Result: Further increased the protective effect of [Necrostatin-1/Sanglifehrin A] combination therapy in renal IRI model.
References	[1]. Sam Hofmans, et al. Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. J Med Chem. 2016 Mar 10;59(5):2041-53. [2]. Andreas Linkermann, et al. Synchronized renal tubular cell death involves ferroptosis.Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16836-41. [3]. Yan Zhang, et al. Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. Brain Res. 2019 Mar 1;1706:48-57.

Density	1.3±0.1 g/cm3
Boiling Point	614.9±55.0 °C at 760 mmHg
Molecular Formula	C₂₆H₃₂N₄O₂
Molecular Weight	432.558
Flash Point	325.7±31.5 °C
Exact Mass	432.252533
LogP	4.93
Vapour Pressure	0.0±1.8 mmHg at 25°C
Index of Refraction	1.656

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1793052-96-6	247085-49-0
15743-56-3	1357349-91-7
14932-53-7	75478-98-7
1150586-64-3	13982-14-4
1802392-86-4	648881-58-7
1442076-40-5	1435976-29-6
1435905-58-0	1574470-76-0
1435982-36-7	1401529-38-1
1435988-69-4	1435996-36-3
1435978-65-6	1491132-25-2